To investigate the mechanism of expression of atrial natriuretic polypeptide (ANP) in human ventricles, we conducted an immunohistochemical study of ANP in biventricular endomyocardial biopsy specimens obtained from a total of 49 patients with cardiac dilatation due to dilated cardiomyopathy (21 patients), postmyocarditis (18 patients), or volume overload (five patients) and subjects with no dilatation as controls (five patients). Four-micron thick sections were stained by an indirect immunoperoxidase method using monoclonal antibody to ahuman ANP as the primary antibody. The frequency of ANP-present myocytes was calculated in each specimen and compared with clinical, echocardiographic, hemodynamic, angiographic, and histologic parameters. ANP-present myocytes were noted in all of the 21 patients with dilated cardiomyopathy, in 11 of the 18 patients with postmyocarditis, in four of the five patients with volume overload, and in zero of the five controls. The mean percentage of ANP-present myocytes was significantly greater in the left-side specimens (35±37%) than in the right-side ones (2±4%o). The percentage of ANP-present myocytes in the left-side specimens significantly correlated with peak systolic or end-diastolic wall stress (r=0.67 and 0.58), left ventricular end-systolic or end-diastolic volume index (r=0.75 and 0.69), or left ventricular end-diastolic pressure (r=0.42) and inversely correlated with ejection fraction (r=-0.73), systolic left ventricular wall thickness (r= -0.58), or cardiac index (r= -0.30). Expression of ANP was rarely seen in the cases with normal wall stresses, normal ejection fraction, normal volume, or normal myocyte size. However, it was seen frequently even in hearts with normal levels of left ventricular end-diastolic pressure and cardiac index (compensated hearts). The percent of ANP-present myocytes in both sides significantly correlated with size of myocytes (r=0.48 at right and r=0.57 at left side) or degree of fibrosis (r=0.45 at right and r=0.48 at left side). These results suggest that ANP expression is augmented in the dilated ventricles regardless of the causes of dilatation and that the augmentation is a compensatory mechanism as prevention against decompensation responding to reduced contractility, excess of wall stresses, or both, concomitantly occurring with cardiac dilatation and myocardial hypertrophy. (Circulation
Atrial natriuretic polypeptide (ANP) is a circulating hormone released from atrial myocytes that regulates the fluid, electrolytes, and vascular homeostasis.1-5 Its plasma concentration increases in patients with congestive heart failure, probably due to compensatory mechanisms. 6 8 In fact, the relation between plasma ANP and hemodynamics has been studied precisely.9-11 ANP is expressed in fetal ventricles, but markedly decreases in normal adult ventricles.12-15 However, in the failing human heart, the hormone is reproduced and resecreted from ventricular myocytes, [16] [17] [18] [19] likewise in animal preparations under various conditions.20-25 Recently, we reported an increase in tissue ANP and ANP gene in the ventricular walls of hearts from patients with dilated cardiomyopathy and ischemic damage from old myocardial infarction. 26 However, it is still not clear which factors, either clinical or pathologic, are contributing or relating to the reexpression of ANP in human ventricles. Therefore, in the present study, using ventricular endomyocardial specimens obtained from human hearts with primary or secondary dilatation, we studied the immunohistochemical expression of ventricular ANP and analyzed its relations to clinical (including hemodynamics and cardiac imagings) and histopathologic parameters.
Methods

Patient Profile
Both right-and left-side endomyocardial biopsy specimens from each of 49 patients were studied. There were 36 men and 13 women (age range, 16-70 years). All patients were evaluated clinically by both noninvasive and invasive methods. Based on clinical, echocardiographic, hemodynamic, angiographic, and histologic findings, patients were assigned to one of the following groups: ventricular dilatation due to dilated cardiomyopathy (21 patients) , ventricular dilatation due to postmyocarditis (18 patients) , ventricular dilatation due to volume overload (five patients), and control subjects without any demonstrative organic cardiac disease (five subjects). The diagnosis of dilated cardiomyopathy was made according to the definition and classification proposed by the World Health Organization-International Society and Federation of Cardiology task force. 27 The postmyocarditis group included patients who had clinical evidence of acute myocarditis more than 1 month earlier, were given the histologic diagnosis of acute myocarditis at the acute stage by the right ventricular endomyocardial biopsy, or both. The right-and left-side endomyocardial biopsies at the late stage, from which the biopsied specimens were used for the present study, revealed persistent, healing, or healed myocarditis. The histologic definition of myocarditis was based on the "Dallas classification system."28 The A monoclonal antibody to a-human ANP was prepared as previously described. 35 The recognized epitope of the monoclonal antibody is located in the N-terminal half of the ring structure of a-human ANP including Met'2 residue. This radioimmunoassay can recognize not only a-human ANP but also ,3-human ANP with a cross-reactivity of 80% on a molar basis and y-human ANP on an equimolar basis. 35 Immunohistochemical reactions according to an indirect immunoperoxidase method36 were performed with some technical modifications. In the first step, intrinsic peroxidase activity was inhibited by the addition of 0.3% hydrogen peroxidase in 0.01 mol/1 phosphate-buffered saline (PBS), and nonspecific binding was blocked with normal goat serum. To inhibit the nonspecific staining of lipofuscin granules that may often have been confusing for the observers, it took as long as 20 minutes for the addition of the hydrogen peroxidase solution. As the primary antibody, the monoclonal antibody was added (dilution of the ascite, 1:1,000) to the sections for 48 hours at 40 C. In the second step, peroxidase-conjugated F(ab')l fragment of the secondary antibody (goat anti-mouse IgG[H+L], Jackson Immunoresearch Laboratories) was added for 45 minutes at room temperature. Then, the sections were stained with 45 mg 3,3'-diaminobenzidine tetrahydrochloride (Sigma Chemical, St. Louis, Missouri) and 0.05% hydrogen peroxide in 100 ml 0.05 mol/1 Tris buffer solution for 3 minutes at room temperature. Between each step, the sections were washed four times (10 minutes each) with 0.01 mol/l PBS. Finally, counterstaining with hematoxylin or periodic acid shift (PAS) was carried out. PAS staining was used to confirm the absence of the pulse-conducting system. The specificity of the immunologic reactions was controlled by replacing the primary antibody with normal mouse serum or PBS. A tissue preparation of the right atrial appendage obtained from a patient during aortocoronary bypass surgery was used as a positive control section.
The presence of immunoreactive ANP was assessed by light microscopic examination. Using the largest of the two or three specimens obtained from each of the right and left ventricular biopsies, ANP in the myocyte was graded as present or absent, and the percentage of ANP-present myocytes to a total of 30-50 arbitrarily selected myocytes with clearly cut nuclei in each specimen was calculated. Two blinded trained observers reviewed the sections. The ventricular end-diastolic pressure (LVEDP) was significantly elevated in dilated cardiomyopathy compared with the controls. EF was significantly reduced in the hearts with dilated cardiomyopathy and volume overload compared with controls, whereas no difference in CI was seen between the groups. Sed and Sps of dilated cardiomyopathy and Sed of postmyocarditis were significantly greater than those of controls. There was no significant difference in age, sex distribution, duration of illness, and heart rate between any of the groups. In the volume-overload group, the mean regurgitant fraction was 27±6% (20-34%). Table 2 summarizes the histopathologic data on the biopsy specimens. Left-side biopsy specimens of all of the diseased groups showed larger myocytes and a greater degree of fibrosis than in the control group. In all groups, the size was greater in the left-side than in the right-side specimens. Immunohistochemical Expression ofANP ANP was observed as a fine, granular, darkbrown immunoreactive substance in the cytoplasm of ventricular myocytes in dilated hearts (Figure 1) . It tended to concentrate around the nuclei, although it was also distributed in the peripheral cytoplasm. Lipofuscin granules were much bigger and not dark brown and, therefore, could be easily distinguished from ANP granules. No immunopositive substances were seen in the endocardium or any of the connective tissues. None of the specimens contained the pulse-conducting system. The sections without primary antibody did not show any immunoreactivity ( Figure 1) . As a positive control section, the tissue preparation from the right atrial appendage showed very strong immunoreactivity in the cytoplasm of the myocytes (Figure 1) .
The incidence of patients with ANP-positive ventricles was zero of the five control patients, 21 of the 21 patients with dilated cardiomyopathy, 11 of the 18 patients with postmyocarditis, and four of the five patients with aortic regurgitation. The mean percentage of ANP-present myocytes in the right-and leftside specimens were 2±4% and 53±33% in dilated cardiomyopathy, 2±4% and 21±35% in postmyocarditis, and 3±5% and 42±43% in aortic regurgitation ( Table 2 ). In the left-side specimens, it was greater in dilated cardiomyopathy than in postmyocarditis.
In all groups with diseased hearts, the incidence of the specimens with ANP and the mean percentage of ANP-present myocytes were higher in the left than in the right-side specimens (Tables 2 and  3) . A correlation was noted between the mean percentage of ANP-present myocytes in the left and the right sides (Figure 2 ). Relations of Ventricular ANP to Clinicopathologic Parameters Table 4 shows the coefficients of correlation between the percentage of ANP-present myocytes in the right-or left-side biopsy specimens and clinicopathologic parameters in the patients examined. Duration of illness did not correlate with the percentage of ANP-present myocytes in each side. The percentage of ANP-present myocytes in the right-and left-side specimens were correlated with EDVI, ESVI, LVEDP, and RVSP and were inversely correlated with VSTS and EF ( Figure 3) . The percent of ANP-present myocytes in the leftside specimens was positively correlated with both Sed and Sps and was inversely correlated with LVTs and CI (Figures 3 and 4) . However, it showed no correlation with LVTd, VSTd, LVSP, RVEDP, or heart rate. A significant correlation was seen between LVEDP and RVSP (r=0.70,p<0.001).
The percentage of ANP-present myocytes in the left-and the right-side biopsy specimens correlated with the mean size of myocytes and the grade of fibrosis ( Figure 5 ). However, it did not correlate with the number of inflammatory cells in either of the two sides.
In the left-side specimens, ANP-present myocytes were seen in only a few cases of the hearts with normal range of EF, sR, Sed, EDVI, ESVI, or myocyte size, whereas they were noted in many of the hearts with normal CI or LVEDP range (Figures 3-5 ).
Discussion
The monoclonal antibody to a-human ANP that we used had cross-reactivities of 80% with /-human ANP and 100% with y-human ANP.35 Thus, we showed that it was also augmented in the dilated heart due to ischemic damage (old myocardial infarction).26 Thus, ventricular ANP is likely to be augmented in dilated hearts regardless of the cause of dilatation. However, significant differences were seen between the groups of patients with dilated cardiomyopathy and postmyocarditis in both the incidence of the patients with ANP-present myocytes and the mean percentage of ANP-present myocytes in the left-side specimens; those of patients with dilated cardiomyopathy were greater than those with postmyocarditis. Compared with postmyocarditis group, the dilated cardiomyopathy group's EDVI, ESVI, S Sed, and myocyte size were significantly greater and VSTS, LVT,, and EF were significantly less. Therefore, the difference of degree of ventricular ANP expression may be explained by the differences of hemodynamics or histologic variables rather than by disease specificity. To check on sampling errors, we examined the variability of the percentage of ANP-present myocytes between different sections of the same specimen and among different specimens from the same patient. The variability was minimal: 1 +±1% in the different sections of the same specimen and 3+±2% in the different specimens from the same patient. However, some variant specimens were also seen in this study, although the correlations were indeed significant between ventricular ANP and various clinical or morphologic parameters. These may be attributed to the limitation of a biopsy study, which is too small to represent the whole ventricle.
Although all medications were stopped on the day of invasive examination, we believe their influences cannot be completely negligible. However, we did not analyze the influence of the drugs on ventricular ANP expression. The strict analysis was impossible because varying amounts and combina-1001 LVB tions of many drugs had been given to the patients according to their clinical states. To date, there have been no strict data on the intervention of drugs on ANP in humans, and, therefore, further analyses are expected in this field.
Last, the benefits of the semiquantitative immunohistochemical method for ANP used in this study were that a direct comparison with histopathologic findings in the same tissue was possible and that formalin-fixed, paraffin-embedded tissue blocks were available.
Conclusion
Ventricular expression of ANP was immunohistochemically demonstrated in endomyocardial biopsy specimens obtained from various forms of cardiac dilatation, and its augmentation is likely to be one of various compensatory mechanisms in response to reduced contractility, excess of ventricular wall stresses, or both. JHypertens 1986;4(suppl 2):S119-S123
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